Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
Subscription to La Merie Publishing’s proprietary Antibody Database provides online access to information about more than 7,100 project entries (as of June 2024) for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their
- Technology (e.g. antibody-drug conjugate, bispecific, isotype, phage display)
- Target (e.g. Her2, CD20, PD-1/PD-L1, CLDN18.2, CD38)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Vectorized Antibodies (in vivo expression)
- Masked Antibodies
- TCR-like Antibodies
- T-Cell Engaging Antibodies
- Natural Killer (NK) Cell Engaging Antibodies
- Biosimilar and Biosuperior Antibodies
- Sales Data of more than 120 therapeutic antibodies (incl. sales history)
Prerequisite: Internet access
Purchase of the subscription provides a 1-year online access to the data of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the Antibody Pipeline Database:
- Intuitive use
- Designed for structured searches
- Focused on targets, therapeutic areas and R&D phases
- Ideal for competitor analysis (companies, targets, technologies, R&D phase)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target
- Class of Compound
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Therapeutic Areas:
- Cardiovascular & blood
- Dermatology
- Gastrointestinal
- Genitourinary, renal & gynecology
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmology & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Predefined Technologies Scroll-Down Menu – examples:
- Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD)
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- In vitro generated Antibodies (phage display)
- Fab Antibodies
- Fc-Fusion Proteins
- Agonist Antibodies
- Transgenic Mouse Antibodies (e.g. XenoMouse, VelocImmune Mouse, KM Mouse)
- Human Cell-Derived Antibodies
Predefined Targets of the Scroll Down Menu – examples:
- Antibody-Drug Conjugates (ADC)
- Antibody Sales in 2022
- Biosimilar Antibody Sales in 2022
- Biosimilar Antibodies
- Biosuperior Antibodies
- CLDN6 Antibodies
- 2 Antibodies
- c-MET/HGF Inhibitors
- CD20 Antibodies
- DLL3 Antibodies
- GPC3 Antibodies
- Her2 Antibodies
- IGF-1R Antagonists
- Immunocytokines
- Immunotoxins
- Interleukin-12/23 Antagonists
- Interleukin-13 Antagonists
- Interleukin-17 Antagonists
- Mesothelin Antibodies
- PSMA Antibodies
- ROR1 Antibodies